Pfizer begins study of oral drug for prevention of COVID-19

imageWorld4 minutes ago (Sep 27, 2021 03:22PM ET)

(C) Reuters. FILE PHOTO: Pfizer logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) -Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.

The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG (OTC:RHHVF), have been racing to develop an easy-to-administer antiviral pill for COVID-19.

The mid-to-late-stage study will test Pfizer (NYSE:PFE)’s drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.

In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

To date, Gilead Sciences Inc (NASDAQ:GILD)’s intravenous drug remdesivir is the only approved antiviral treatment for COVID-19 in the United States.

Pfizer has also started another study of PF-07321332 in non-hospitalized, symptomatic adult patients.

Merck and partner Ridgeback Biotherapeutics recently launched a late-stage trial of their experimental drug molnupiravir for prevention of the COVID-19 infection.

Molnupiravir is also being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

Pfizer begins study of oral drug for prevention of COVID-19

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles

Evergrande, EV unit shares jump after chairman signals business shift

Stock Markets8 minutes ago (Oct 24, 2021 10:16PM ET) 2/2 (C) Reuters. FILE PHOTO: An aerial view shows residential buildings at the construction site of Evergrande...

Dollar catches footing as inflation pressures rates outlook

Economy43 minutes ago (Oct 24, 2021 09:40PM ET) (C) Reuters. FILE PHOTO: An employee of the Korea Exchange Bank counts one hundred U.S. dollar notes...

Oil prices on the march again in tight market; U.S. crude at 7-yr high

Commodities58 minutes ago (Oct 24, 2021 09:25PM ET) (C) Reuters. FILE PHOTO: Crude oil storage tanks are seen from above at the Cushing oil hub,...

Latest Posts

Stay in touch

Join the exclusive subscription today and get premium articles for free

Categories